Day: April 5, 2022

SAMPO PLC                               ANNUAL FINANCIAL REPORT         5 April 2022 at 9:30 amSampo Group’s annual reporting for 2021 Sampo has published its annual reporting documents for 2021 at www.sampo.com/year2021 . For the second time, the Board of Directors’ Report and Financial Statements are published in accordance with the European Single Electronic Format (ESEF) reporting requirements. The format is Extensible Hypertext Markup Language (XHTML), and the primary statements have been labelled with XBRL tags. The firm of authorised public accountants Deloitte Ltd has provided an independent auditor’s reasonable assurance report on Sampo’s ESEF Financial Statements in accordance with ISAE 3000 (revised). In addition to the Board of Directors’ Report and Financial Statements, the following reviews and reports for the year 2021...

Today, Tryg is publishing a newsletter titled “An introduction to IFRS 17”. In the document Tryg is showing the impact on the introduction of IFRS 17 on its 2020 figures, the changes to the financial statements are very limited. Shareholders’ equity and net profit are completely unchanged while the technical result is modestly higher. Tryg is a pure non-life player with a relatively low duration of the liabilities, both assets are liabilities are presented fully at mark to market, these characteristics together with conscious choices ensure stability in the presentation of the results also under IFRS 17.AttachmentNewsletter_An introduction to IFRS 17

Medesis Pharma wishes to accelerate the development of its antinuclear products and provides an update on its strategy Montpellier (France), April, 5, 2022 – 8:45am – Medesis Pharma (ISIN: FR0010844464, Ticker: ALMDP), a pharmaceutical biotechnology company developing drug candidates with its proprietary buccal active ingredient delivery technology, Aonys®, publishes an information note on the three future drugs in development for the protection of large populations contaminated after a civil or military nuclear accident. Three drugs are specifically intended for the treatment of large populations contaminated or irradiated after a civil or military nuclear accident. To date, there is no suitable treatment for a serious nuclear accident. The three products are at the heart of the issues with the tragic international situation in...

Company announcement April 5, 2022 Announcement No. 9/2022 Capital Markets Day 2022 Today, Nilfisk A/S is hosting a Capital Markets Day at the company headquarter in Brøndby, Denmark, for investors and analysts. The event will be open for both physical and virtual attendance. The event will detail Business Plan 2026 including financial targets towards 2026 through a series of presentations outlined below. There will be opportunity to ask questions to the speakers. Topic 1: Business Plan 2026CEO Torsten Türling will introduce the day by outlining the strategic direction and Business Plan 2026.  CFO Reinhard Mayer will go through financial targets towards 2026 and talk about how Nilfisk is building a strong execution engine. EVP, Head of HR Jacob Blom will provide insight into ‘Culture for successful strategy execution’.Topic 2: Growth...

SN Aboitiz Power Group (SNAP), a joint venture between Scatec and AboitizPower, has made the final investment decision for the 20 MW battery energy storage system (BESS) project at the Magat hydropower plant in Ramon, Isabela in the Philippines.   The project is now making final preparations for construction start later in 2022, with a targeted commercial operation date in 2024, and marks the first venture between the country’s leading provider of renewable energy AboitizPower and Scatec, after the Norwegian renewable energy solutions provider acquired SN Power. “We are excited about technologies like BESS that complement our ambition of bringing forth an RE-powered future, and continue to explore and assess other greenfield and brownfield opportunities beyond hydropower and floating solar. We also appreciate the support of our banking...

CGG and Kent Announce Strategic Carbon Capture & Hydrogen Partnership to Accelerate Global Decarbonisation Paris, France – April 5, 2022 CGG, a global technology leader in geoscience, has announced a strategic partnership with Kent, a leading energy services engineering company, to work together on realizing decarbonisation opportunities through CCUS development and hydrogen production and supply. CGG and Kent will be providing customers in the energy and industrial sectors with ‘end-to-end’ services across the life cycle of the projects. For example, from subsurface characterization required for storage screening and evaluation to project engineering, planning, construction, and commissioning, including late-life activities such as decommissioning and long-term monitoring, that include instrumentation and data management. This collaboration...

Press release Paris La Défense, 5 April 2022 Governance changes Marie-Claire Daveu has informed Albioma today of her intention to resign from the Board of Directors with effect from 31 July 2022, with her appointment as Director to be submitted to Engie’s General Meeting of Shareholders shortly. The composition of the Board of Directors of Albioma will be reviewed accordingly in the coming months. Frédéric Moyne, Chairman and CEO of Albioma, said: “I would like to join all the directors in thanking Marie-Claire Daveu for her outstanding contribution to the work of the Board, particularly in her role as Chair of the Corporate Social Responsibility Committee. She has been one of the key players in the Group’s excellence in sustainable development.” Next on the agenda: revenue figures for the first quarter of the 2022 financial...

Figure 1 Kaplan Meier – Preliminary survival rate analysis of Roll-In Cohort, dated 25 March 2022Reporting of primary endpoint on track for Q4 2022 FDA regulatory submission on track for mid-202370% survival of POSEIDON Roll-In patients at one year post-implantation1 compares favourably to published literature in this high-risk patient populationGHENT, Belgium, April 05, 2022 (GLOBE NEWSWIRE) — Sequana Medical NV (Euronext Brussels: SEQUA) (the “Company” or “Sequana Medical”), an innovator in the treatment of diuretic-resistant fluid overload in liver disease, malignant ascites, and heart failure, today announces that it has completed implanting patients in POSEIDON, the North American pivotal study to support regulatory approval of the alfapump system in the U.S. and Canada, for the treatment of...

Four-year collaboration to investigate the potential of IBA’s ConformalFLASH® technology for the treatment of early-stage breast cancer Louvain-la-Neuve, Belgium, April 5, 2022 IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology, and the University Medical Center Groningen (UMCG) announce today a four-year research collaboration agreement towards development of a new FLASH irradiation protocol for the treatment of early-stage breast cancer. The focus of the partnership will be on building advanced FLASH irradiation techniques and pre-clinical radiobiology models to accelerate the validation and adoption of IBA’s ConformalFLASH®1 technology for use in pre-operative early breast cancer treatment. ConformalFLASH® is a novel delivery technique combining ultra-high dose rate FLASH radiotherapy with...